PANACRO HKEX IPO Filing Lapses; Clinical CRO Gross Margin of 38.3% Exceeds Industry Average

NewTimeSpace News: The listing application submitted by PANACRO (Hangzhou) Pharmaceutical Technology Co., Ltd. to the HKEX on 11 February 2026 has lapsed, as it has been pending for six months. CISI FIN and ICBC International served as the original joint sponsors.

The Company is a clinical contract research organization (CRO) headquartered in Hangzhou, China, dedicated to empowering innovative drug clinical research through digital enablement. Its services span the full clinical development process, covering investigational new drug (IND) applications, Phase I-IV clinical studies, new drug application (NDA) regulatory filings, functional service provider (FSP) services and other offerings.

The Company has demonstrated notable operational efficiency and profitability. In 2024, its gross margin reached 38.3%, higher than the industry average of approximately 30%; its net margin was 19.8%, higher than the industry average of approximately 10%; and its revenue per employee was RMB 0.85 million, exceeding the industry average of approximately RMB 0.55 million. Since its establishment in 2004, the Company has advanced strategic initiatives including the transformation toward innovative drug clinical research, prioritized deployment in oncology and autoimmune disease therapeutic areas, in-house development of digital systems, and international business expansion.

The Company operates more than 20 service sites across major Chinese cities, along with subsidiaries and localized teams in the United States and Australia. Its clients include over 200 innovative pharmaceutical and biotechnology companies, such as BUCHANG PHARMA and BAIYUNSHAN PH, with some client relationships spanning more than a decade.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.